Novo Nordisk AS (N1VO34)

B3


	Symbol		Exchange		Currency
	N1VO34		B3		BRL	Delayed
	NOVOBc		BATS Europe		DKK	Delayed
	NVO		NYSE		USD	Real-time
	0QIU		London		DKK	Real-time
	NVON		Mexico		MXN	Delayed
	NOVG		Dusseldorf		EUR	Delayed
	NOVG		Xetra		EUR	Delayed
	NOVG		Frankfurt		EUR	Delayed
	NVONy		TradeGate		EUR	Delayed
	NOVOb		Copenhagen		DKK	Real-time
	NNO2		Vienna		EUR	Real-time

Currency in BRL

Disclaimer

78.64

-0.96(-1.21%)

Closed01:28:59

Fair Value

Day's Range

78.64

80.00

52 wk Range

57.03

102.82

N1VO34 Income Statement

Featured here, the Income Statement (earnings report) for Novo Nordisk AS, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

122,021

126,946

140,800

176,954

232,261

Total Revenues Growth

+9.11%

+4.04%

+10.91%

+25.68%

+31.26%

Cost Of Revenues

20,088

20,932

23,658

28,448

35,765

Gross Profit

101,933

106,014

117,142

148,506

196,496

Gross Profit Growth

+8.19%

+4%

+10.5%

+26.77%

+32.32%

Gross Profit Margin %

83.54%

83.51%

83.2%

83.92%

84.6%

Other Operating Expenses, Total

49,450

51,888

57,925

72,937

92,508

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+5.29%	+4.93%	+11.63%	+25.92%	+26.83%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	14,220	15,462	17,199	23,287	31,029
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	35,830	36,886	41,058	50,684	61,598
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-600	-460	-332	-1,034	-119

Operating Income

52,483

54,126

59,217

75,569

103,988

Operating Income Growth

+11.08%

+3.13%

+9.41%

+27.61%

+37.61%

EBIT Margin %

43.01%

42.64%

42.06%

42.71%

44.77%

Net Interest Expenses

-155

-53

-58

-139

527

Net Interest Expenses Growth

-355.88%

+65.81%

-9.43%

-139.66%

+479.14%

Interest Expense, Total

-220

-390

-289

-378

-542

Interest And Investment Income

65

337

231

239

1,069

Other Non Operating Expenses, Total

-3,630

-748

198

-5,021

1,536

EBT, Excl. Unusual Items

48,698

53,325

59,357

70,409

106,051

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-

-

-573

-760

-1,414

EBT, Incl. Unusual Items

48,553

53,130

59,080

69,062

104,674

EBT, Incl. Unusual Items Growth

+1.97%

+9.43%

+11.2%

+16.9%

+51.57%

EBT, Incl. Unusual Items Margin

39.79

41.85

41.96

39.03

45.07

Income Tax Expense

9,602

10,992

11,323

13,537

20,991

Net Income to Company

38,951

42,138

47,757

55,525

83,683

Minority Interest

-

-

-

-

-

Net Income

38,951

42,138

47,757

55,525

83,683

Net Income Growth

+0.84%

+8.18%

+13.33%

+16.27%

+50.71%

Net Income Margin %

31.92%

33.19%

33.92%

31.38%

36.03%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

38,951

42,138

47,757

55,525

83,683

Basic EPS - Continuing Operations

8.2

9.03

10.4

12.26

18.67

Basic EPS - Continuing Operations Growth

+2.76%

+10.05%

+15.18%

+17.87%

+52.32%

Diluted EPS - Continuing Operations

8.19

9.01

10.37

12.22

18.62

Diluted EPS - Continuing Operations Growth

+2.82%

+9.95%

+15.16%

+17.84%

+52.37%

Basic Weighted Average Shares Outstanding

4,748.6

4,667.8

4,593.2

4,530.6

4,482.8

Diluted Weighted Average Shares Outstanding

4,757.4

4,680

4,606.2

4,544.6

4,494.8

Dividend Per Share

4.18

4.55

5.2

6.2

9.4

Dividend Per Share Growth

+2.45%

+8.98%

+14.29%

+19.23%

+51.61%

EBITDA

56,310

58,565

63,770

80,875

109,813

EBITDA Growth

+10.04%

+4%

+8.89%

+26.82%

+35.78%

EBITDA Margin %